Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
about
Medical interventions for the prevention of platinum-induced hearing loss in children with cancerMedical interventions for the prevention of platinum-induced hearing loss in children with cancerCisplatin ototoxicity and protection: clinical and experimental studiesPediatric and Adolescent Extracranial Germ Cell Tumors: The Road to CollaborationPrevention and restoration of hearing loss associated with the use of cisplatin.Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention.Cisplatin and cranial irradiation-related hearing loss in children.Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.Pilot study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high risk germ cell tumors: a report of the children's oncology group (COG)Auditory late effects of childhood cancer therapy: a report from the Children's Oncology GroupProtective effect of metformin against cisplatin-induced ototoxicity in an auditory cell line.Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria.Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastomaAmifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections.Genetic variants associated with cisplatin-induced ototoxicity.Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group.Clinically accurate assessment and grading of ototoxicity.Ten challenges in the management of neuroblastoma.Is there a role for carboplatin in the treatment of malignant germ cell tumors? A systematic review of adult and pediatric trials.Paediatric genitourinary cancers and late effects of treatment.Ototoxicity and cancer therapy.Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.Carvedilol protects against apoptotic cell death induced by cisplatin in renal tubular epithelial cells.Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.Protein Synthesis Inhibition and Activation of the c-Jun N-Terminal Kinase Are Potential Contributors to Cisplatin Ototoxicity.Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection.Acquired sensorineural hearing loss in children: current research and therapeutic perspectives.Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.Ototoxicity: A Challenge in Diagnosis and Treatment.Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach.Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
P2860
Q24194929-B2745765-B243-4B6C-BDFB-3DE1398F8C3DQ24197812-FC347EE2-8F8C-4FB8-8A18-8767BCB3CD86Q24628775-0151F9A9-E0AA-4E84-AA1F-89D3DB2B05D0Q26797518-5F8CB536-C275-4248-AC5B-20B15D399997Q26825493-753E9070-0D39-4EB7-B2C1-6A6B789B072DQ30447637-997D7BB4-02FA-4C86-928D-36C3F4C62D20Q30462703-2D23E00A-A054-4FE9-81DB-E72374E09AD9Q30578179-555AEEA2-1FA7-4F58-B97A-5164161039F3Q33638876-6877308B-744F-44E2-A2D4-D4434778AB9EQ34797430-8DC78EDE-AF5B-42C7-8E43-DEF365FC3640Q34999814-F165D5FA-D9E7-4E60-BABD-E83FEEBC62A2Q35019735-56C3F44A-26D0-4DFC-8690-046E976BC897Q35057783-CFDFB0F0-AD86-48A4-8BFA-7EDFB213E4D1Q36035287-CD784A07-8F68-46BB-BB07-EF568777F686Q36057728-31BAB41F-6580-4CE6-AB4B-13335FAC19D3Q36358551-765E355F-9896-4531-8634-648CF7CC286DQ36825081-6C9B49AC-A637-4994-8970-BB4493FA5E1AQ37289140-8D4D28D5-9E43-40AC-93F5-2B716948DDB8Q37293994-4F0E54CA-4695-42D7-B61A-19A6D10EF526Q37480824-3C4B3C76-D6A6-4E9F-998F-B9B202226B3CQ37959903-FBBDE81C-1291-458B-BE92-B2625D4A1F2BQ38029366-FE3A82D9-5295-42D3-8832-C53164EE55BFQ38043415-36AF31BF-46F9-459E-8E57-73111658E328Q38062820-741AD784-EA5F-4AA2-9C1B-1A355E68E96BQ38727368-27AE0C05-5BE2-4CCA-992C-3B23AA2F00EAQ38964704-6E54AE69-F2F2-4C68-B037-9A623F009E84Q39304222-A5C6C5AF-F273-42CC-B504-9C933C7D0457Q40443233-C09A9CEC-3DFE-4DD9-B91B-BC99E2A9C3A7Q42369948-FAED86CC-99F4-41D0-AEDA-36229728C080Q46256727-355FBCC6-90F0-43DF-B25D-415B03D2628EQ47554578-ECB9D623-C32E-4974-9296-BBE9D56B9271Q47716828-C9298032-CA63-42F4-BC84-C5CC30CD5629Q50300972-B26272DC-981B-47A3-8FC0-3D1F4D153F15Q50433278-B3070677-7279-4CC1-96EF-2D418A93A9FBQ50456063-CC983764-A277-4CB5-B644-7BD5A8722B80
P2860
Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Amifostine does not protect ag ...... ildren's Oncology Group study.
@ast
Amifostine does not protect ag ...... ildren's Oncology Group study.
@en
type
label
Amifostine does not protect ag ...... ildren's Oncology Group study.
@ast
Amifostine does not protect ag ...... ildren's Oncology Group study.
@en
prefLabel
Amifostine does not protect ag ...... ildren's Oncology Group study.
@ast
Amifostine does not protect ag ...... ildren's Oncology Group study.
@en
P2093
P356
P1433
P1476
Amifostine does not protect ag ...... ildren's Oncology Group study.
@en
P2093
A Lindsay Frazier
Children's Oncology Group
Elizabeth J Perlman
Frederick Rescorla
Marcio Malogolowkin
Mary M Davis
Neyssa Marina
Richard B Womer
Roger Giller
Stephen J Lauer
P304
P356
10.1002/CNCR.21218
P407
P577
2005-08-01T00:00:00Z